A003520 Stock Overview
Operates as a pharmaceutical company in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Yungjin Pharm. Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,075.00 |
| 52 Week High | ₩2,790.00 |
| 52 Week Low | ₩1,823.00 |
| Beta | 0 |
| 1 Month Change | 4.80% |
| 3 Month Change | -19.10% |
| 1 Year Change | 0.97% |
| 3 Year Change | -58.75% |
| 5 Year Change | -64.16% |
| Change since IPO | -96.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| A003520 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -1.9% | -2.3% | 0.3% |
| 1Y | 1.0% | 11.7% | -1.5% |
Return vs Industry: A003520 underperformed the KR Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: A003520 exceeded the KR Market which returned -1.5% over the past year.
Price Volatility
| A003520 volatility | |
|---|---|
| A003520 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A003520 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A003520's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | n/a | Chae-Joon Lee | www.yungjin.co.kr |
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. The company also provides vitamins, minerals, and other products; and APIs.
Yungjin Pharm. Co., Ltd. Fundamentals Summary
| A003520 fundamental statistics | |
|---|---|
| Market cap | ₩379.50b |
| Earnings (TTM) | ₩8.53b |
| Revenue (TTM) | ₩158.79b |
0.0x
P/E Ratio0.0x
P/S RatioIs A003520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A003520 income statement (TTM) | |
|---|---|
| Revenue | ₩158.79b |
| Cost of Revenue | ₩99.50b |
| Gross Profit | ₩59.28b |
| Other Expenses | ₩50.76b |
| Earnings | ₩8.53b |
Last Reported Earnings
Sep 30, 2013
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A003520 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/18 23:18 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2013/09/30 |
| Annual Earnings | 2012/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Yungjin Pharm. Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|